| Identification | Back Directory | [Name]
Dirlotapide | [CAS]
481658-94-0 | [Synonyms]
CP742033
Slentrol
Dirlotapide
1H-Indole-2-carboxamide, 1-methyl-N-[(1S)-2-[methyl(phenylmethyl)amino]-2-oxo-1-phenylethyl]-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]- | [Molecular Formula]
C40H33F3N4O3 | [MDL Number]
MFCD27976718 | [MOL File]
481658-94-0.mol | [Molecular Weight]
674.71 |
| Chemical Properties | Back Directory | [Boiling point ]
821.2±65.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
12.40±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Treatment of obesity in companion animals (dogs) (gut microsomal triglyceride transport protein (gMTP) inhibitor) . | [Veterinary Drugs and Treatments]
Dirlotapide oral solution is indicated for the management of obesity
in dogs. | [in vivo]
Dogs receiving 0.3 mg dirlotapide/kg once daily have a small but significant (P=0.018) decrease (6.16 ± 2.22%, mean ± SD) in crude fat digestibility compared with the placebo-treated food-restricted dogs, but no difference in crude protein, dry matter, or energy digestibility is observed. Dirlotapide effectively reduces appetite and energy intake without affecting nutrient digestibility, except for a minimal decrease in fat digestibility[1]. Dirlotapide (0.5 mg/kg) results in a high rate of weight loss (3.3% weekly) and anorexia, emesis, and loose stools for some dogs. Dirlotapide produces weight loss by both reducing appetite (about 90% of the weight loss activity) and by increasing fecal fat excretion (about 10% of the weight loss activity)[2]. | [storage]
Store at -20°C |
|
|